In spite of the clinical efficiency of lapatinib in breast cancer patients, some ERBB2-expresing tumors are not responsive to this treatment and some patients that do initially respond, acquire lapatinib resistance [8, 9]. This evidence concerns the gene ERBB2 and breast cancer.